Rigel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Rigel Pharmaceuticals

02/05/2023 22:02

* Rigel Pharmaceuticals Inc  RIGL.OQ  reported a quarterly
adjusted loss of 8 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 10 cents per share.
    * Revenue rose 55.8% to $26.07 million from a year ago;
analysts
expected $24.07 million. 
    * Rigel Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 8 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Rigel Pharmaceuticals Inc shares had fallen by 9.8% this
quarter and lost 20.7% so far this year.
    * The company reported a quarterly loss of $13.36 million.
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
2 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.10          -0.08          Beat
 Dec. 31 2022      -0.11          0.01           Beat
 Sep. 30 2022      -0.13          -0.11          Beat
 Jun. 30 2022      -0.12          -0.08          Beat